Dermatitis Atopik

01Pathophysiology

Atopic dermatitis is best understood as a disease of two interacting failures: a defective epidermal barrier and a dysregulated immune response. The single most heavily tested mechanistic concept is the filaggrin gene mutation. Filaggrin is a structural protein essential for aggregating keratin filaments and forming the cornified envelope of the stratum corneum. Loss-of-function mutations in the filaggrin gene lead to a defective, "leaky" skin barrier, which causes increased transepidermal water loss, resulting in the clinically obvious xerosis (dry skin) that is nearly universal in these patients.

This barrier defect matters because it does more than just dry the skin — it also allows increased penetration of environmental allergens, irritants, and microbial antigens into the epidermis and dermis. Once inside, these antigens are taken up by Langerhans cells and presented to naive T cells, driving a T-helper 2 (Th2)-predominant immune response in the acute phase. Th2 cytokines — particularly interleukin-4 and interleukin-13 — are the key mediators tested on exams, because they are the specific targets of dupilumab (a monoclonal antibody against the IL-4 receptor alpha subunit shared by both cytokines). This Th2 skew also drives B-cell class switching to IgE production, which explains the elevated serum IgE frequently found in these patients, even though IgE elevation is not required for diagnosis.

The intense pruritus that defines this disease is driven directly by these same inflammatory cytokines (IL-4, IL-13, and IL-31) acting on cutaneous sensory nerve fibers. This produces the classic "itch-scratch cycle": pruritus leads to scratching, scratching causes further mechanical disruption of an already-defective barrier, and this disruption triggers more inflammation and more itch. Chronic scratching over time produces lichenification (thickened, leathery skin with accentuated skin markings), which is why the clinical morphology shifts from acute, oozing, weeping lesions in infancy to dry, thickened, lichenified plaques in chronic or adult disease.

Finally, the disrupted barrier and altered local immunity favor Staphylococcus aureus colonization, found on the skin of the majority of these patients even in areas that appear uninvolved. This colonization is not incidental — staphylococcal superantigens further amplify the local inflammatory response, which is why secondary bacterial infection is a common complication and why some patients benefit from measures that reduce bacterial burden, such as dilute bleach baths.

02Classification and Clinical Manifestation

A related concept the exam likes to test is the "atopic march": atopic dermatitis in infancy tends to precede, and is a risk factor for, the later development of food allergy, allergic rhinitis, and asthma — in roughly that chronological order.

03Diagnostic Workup

The critical exam point here is that atopic dermatitis has no confirmatory laboratory or histologic gold standard — it is diagnosed clinically based on morphology, distribution, chronicity, and personal or family atopic history. Ordering an IgE level as the "next step" to confirm the diagnosis is a classic distractor answer; the correct next step is almost always clinical assessment and, in an established patient with a sudden worsening, evaluation for secondary infection. The one scenario where biopsy or culture genuinely changes management is when the presentation is atypical (asymmetric, poorly responsive to therapy, or suggestive of an infectious or malignant mimic such as cutaneous T-cell lymphoma in an older adult).

04Management and Treatment

Acute management of a flare centers on anti-inflammatory control: a topical corticosteroid of appropriate potency for the affected body site, applied for a limited course, combined with aggressive emollient use. Long-term management is about maintenance — continuous emollient use, trigger identification and avoidance (harsh soaps, wool fabrics, extremes of temperature, sometimes specific food or environmental allergens), and stepping down to the lowest effective therapy once controlled, sometimes using proactive intermittent topical anti-inflammatory application ("weekend therapy") to prevent relapse in previously affected areas.

A key contraindication and dosing point that is heavily tested: prolonged, high-potency topical corticosteroid use on the face, eyelids, or skin folds risks cutaneous atrophy, telangiectasia, and periorificial dermatitis — this is precisely why topical calcineurin inhibitors exist as an alternative for those sites. Topical calcineurin inhibitors themselves carry a boxed warning regarding a theoretical malignancy risk, though this is not considered clinically significant with appropriate use.

The single most important "next best step" scenario on this topic is the patient with well-controlled atopic dermatitis who develops sudden, painful, monomorphic, "punched-out" vesicles or erosions, sometimes with fever — this is eczema herpeticum, a dermatologic emergency caused by disseminated herpes simplex virus infection through the disrupted skin barrier. The correct next step is prompt initiation of systemic (typically intravenous) acyclovir, not simply escalating topical steroids, which would worsen a viral infection.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students miss questions on this topic is by over-ordering tests — reflexively selecting "check serum IgE" or "skin biopsy" as the next step when the vignette already gives a classic clinical picture (infant with itchy, oozing facial patches sparing the diaper area, or a child with flexural lichenified plaques and a family history of asthma). The exam is testing whether you recognize that atopic dermatitis is a clinical diagnosis, and that reaching for labs when the clinical picture is already classic is both unnecessary and the wrong answer. The second major trap is a vignette describing a patient with known, previously stable atopic dermatitis who now develops rapidly worsening, monomorphic vesicular or punched-out lesions with systemic symptoms — failing to recognize eczema herpeticum and instead choosing to simply increase topical steroids is one of the highest-yield "gotchas" in dermatology, because steroids in that setting would worsen the underlying viral infection. Finally, watch for questions distinguishing atopic dermatitis from its mimics purely by distribution and age pattern (flexural in children/adults versus extensor/facial in infants, versus extensor surfaces in psoriasis, versus a specific contact site in allergic contact dermatitis) — the core competency being tested throughout this topic is your ability to use morphology, distribution, and age to drive a clinical diagnosis and to recognize the one true diagnostic emergency (eczema herpeticum) within an otherwise benign, chronic disease.